Navigation Links
4-in-1
Date:5/7/2009

This release is available in German.

Diagnosis and treatment in one go: Korean researchers led by Tae Gwan Park and Jinwoo Cheon have developed the basis for a four-in-one agent that can detect, target, and disable tumor cells while also making them macroscopically and microscopically visible. As they report in the journal Angewandte Chemie, their work involves magnetic iron oxide particles with a fluorescence dye, RNA fragments, and a special peptide attached. The peptide is present to specifically identify the cancer cells; the RNA fragments suppress the special cancer-cell genes, killing the cells. The magnetic particles act as a contrast agent for magnetic resonance imaging, and the fluorescence dye allows for microscopic imaging of the target cells.

In order to build a protein according to the genetic information in a cell, the gene on the DNA is read off and translated into a "stencil", mRNA, which is then used by the cell as a blueprint for the protein. The mRNA is a good point of attack to stop the synthesis of proteins required for tumor growth. To achieve this, siRNAs (small interfering RNAs) are introduced into the cell. These are short, double-stranded RNA fragments that bind specifically to the target mRNA. Inside the cell, a special protein complex binds to the siRNA, which unwinds and cleaves the mRNA. In this unprotected form, the mRNA is rapidly degraded by the cell.

When bound to nanoparticles, the siRNAs are easier to slip into cells. In order to specifically target cancer cells, the particles carry a short peptide, called RGD, which points the way: RGD strongly binds to an integrin, a membrane protein that is anchored to metastasizing tumor cells in much higher amounts than in healthy tissue. The integrins with RGD-equipped nanoparticles are actively brought into the cell interior with their cargo intact (receptor-mediated endocytosis).

The magnetic particles not only act as an aide for transport, they are also a contrast agent for MRI. This reveals where the tumors are, whether the particles are concentrating there, and how the treatment is progressing. If higher resolution is required, the fluorescence dye molecules come into play. In histological slides of tissue samples, they make it possible to see how the magnetic particles are taken up by individual cells an in which cell compartments they are concentrated.


'/>"/>

Contact: Jinwoo Cheon
jcheon@yonsei.ac.kr
82-221-235-631
Wiley-Blackwell
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of the ... is the creation of published author, John Allred, a passionate leader of ministry to ... who has traveled and ministered on four continents. , “It is my hope and ...
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: